Elan announces increased Q1 losses
28/04/2005 - 11:43:46Elan today announced its first quarter 2005 financial results, with $74.7m (€57.8m) net operating losses for the quarter.
Most of the losses were related to its Tysabri drug.
Commenting on Elan’s business, Kelly Martin, Elan’s president and chief executive officer, said: “The voluntary suspension of Tysabri was a disappointment to many constituents including patients, physicians and shareholders.
"We are working closely with the regulatory authorities and Biogen Idec to complete the patient evaluations and develop an appropriate plan for Tysabri."
